GLP-1 Vision Loss Lawsuit

GLP-1 receptor agonists are prescription medications originally used to treat type 2 diabetes and, more recently, to manage chronic weight problems. These drugs mimic glucagon-like peptide-1, a hormone that helps regulate blood sugar levels, insulin secretion and appetite by:

• Increasing insulin production after meals
• Suppressing glucagon, which raises blood sugar
• Slowing gastric emptying
• Enhancing satiety (feeling of fullness), reducing food intake

Because of these effects, GLP-1 drugs have become some of the most widely prescribed metabolic medications in the United States. Their use has expanded rapidly as newer formulations demonstrated substantial weight-loss benefits in addition to glucose control.

Millions of individuals now take these medications, including many patients who use them to treat obesity but don’t have diabetes.

Drug manufacturers are expected to monitor safety after approval and communicate emerging risks to healthcare providers and patients.

Many plaintiffs reported experiencing vision loss as a GLP-1 side effect during or shortly after treatment. Some describe abrupt visual changes that occurred without warning, while others report progressive symptoms that worsened over time.

In some cases, the impairment is permanent and significantly affects independence, employment and daily functioning. Vision loss can also create secondary risks, including difficulty driving, navigating unfamiliar environments and performing routine tasks.

As a result, people have filed lawsuits against manufacturers alleging that they failed to adequately warn about the risk of severe eye injuries.

The lawsuits claim that the drug makers:

• Failed to warn patients and healthcare providers about specific vision risks
• Failed to update safety labeling as new information emerged
• Failed to adequately investigate adverse event reports
• Marketed the drug’s benefits while minimizing risks

Plaintiffs argue that stronger warnings could have prompted closer monitoring, earlier intervention or alternative treatment decisions, and that patients were not informed about symptoms that might signal the development of optic nerve problems.

Because NAION can cause irreversible damage within a short time frame, delayed recognition may have serious consequences.

Drugs and manufacturers involved in the GLP-1 vision loss lawsuits

Both federal multidistrict litigation and state-level litigation involving GLP-1-related vision loss include medications produced by Novo Nordisk and Eli Lilly. These drugs are widely prescribed for type 2 diabetes and chronic weight management and share mechanisms that affect blood sugar regulation and appetite.

Novo Nordisk manufactures several widely used GLP-1 agonist medications, including:

• Ozempic® (semaglutide injection)
• Wegovy® (semaglutide injection for weight loss)
• Rybelsus® (semaglutide oral tablets)
• Saxenda® (liraglutide)
• Victoza® (liraglutide)

Eli Lilly products include:

• Mounjaro® (tirzepatide)
• Zepbound® (tirzepatide for weight loss)
• Trulicity® (dulaglutide)
• Foundayo® (orforglipron)

The GLP-1 vision loss lawsuits focus primarily on non-arteritic anterior ischemic optic neuropathy (NAION). NAION is a serious vision-related side effect of GLP-1 medications that affects the optic nerve. The condition can cause sudden and sometimes permanent vision loss.

Non-arteritic anterior ischemic optic neuropathy (NAION)

Sometimes described as an “eye stroke,” NAION is caused by reduced blood flow to the optic nerve. When that blood flow is disrupted, the nerve may not receive enough oxygen and nutrients. This can damage the fibers responsible for transmitting visual information from the eye to the brain.

The condition often causes sudden, painless vision loss in one eye, especially right after waking up. Some patients experience permanent visual impairment, including blind spots and loss of part of their visual field.

In 2025, a large nationwide cohort study looked at more than 1.5 million patients with type 2 diabetes taking GLP-1 agonist medications. The study found that treatment with semaglutide or tirzepatide was associated with an increased risk of NAION and other optic nerve disorders compared with other diabetes medications.

NAION can cause permanent blindness. There are currently no Food and Drug Administration (FDA) approved medicines to reverse vision loss or prevent worsening in patients with NAION.

Other reported vision problems

Other vision-related problems linked to GLP-1 use include:

• Optic nerve damage: Injury to the optic nerve that can impair visual signaling and contribute to partial or severe vision loss
• Blurred vision or other visual disturbances: Changes in focus, clarity or field of vision that may accompany or precede more serious complications
• Optic disc edema: Swelling of the optic nerve head that may be relevant in evaluating optic nerve dysfunction
• Progression of pre-existing eye disease: Including concerns sometimes raised about diabetic retinopathy progression in susceptible patients

Eligibility generally depends on medical history, drug exposure and documented injury. Factors considered could include:

• Use of a GLP-1 medication before symptom onset
• Diagnosis of NAION or another serious vision disorder
• Medical evidence linking the injury to drug exposure
• Permanent or substantial impairment affecting daily life
• Absence of alternative explanations for the condition

Because NAION often occurs abruptly and can result in lasting impairment, prompt documentation of symptoms and medical findings may be important.

Medical records, ophthalmologic evaluations and treatment history are typically important components of a case review. In some situations, expert analysis may be needed to determine whether a medication could have contributed to the injury.

If successful, victims may receive damages resulting from the injury. The amount and type of compensation depend on the specific facts of each case, including the severity of vision loss and its impact on daily life.

Potential damages may include:

• Medical expenses
• Lost income
• Pain and suffering
• Future care needs

Permanent vision loss can require substantial adaptation, including mobility assistance, visual aids or modifications to living arrangements.

Vision loss can profoundly affect independence and daily functioning. Individuals who experience severe visual impairment may face challenges related to employment, mobility and routine activities. Our team seeks to provide guidance and representation to clients navigating these difficulties.

Our attorneys have represented thousands of patients seriously hurt by dangerous prescription and over-the-counter drugs. If you believe a GLP-1 RA medicine caused vision loss, contact us to review your claim.

Learn more about our medical drug experience here.

Do not stop taking a prescribed medication without first consulting with your doctor. Discontinuing a prescribed medication without your doctor’s advice can result in injury or death. Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda, Trulicity, Victoza and Foundayo remain approved by the U.S. Food and Drug Administration.